The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo

Leukemia Research
Eric SanchezJames R Berenson

Abstract

Panobinostat (LBH589) is a potent histone deacetylase inhibitor (HDACi) that has shown anti-tumor activity in preclinical studies in both solid and hematological malignancies. We evaluated the anti-multiple myeloma (MM) effects of LBH589 alone and with melphalan or doxorubicin using MM cell lines and our human MM xenograft model LAGλ-1. LBH589 treatment resulted in increased acetylation of histones, induction of caspase cleavage, inhibition of cell proliferation and synergistic anti-MM effects with melphalan or doxorubicin in vitro. LBH589 with melphalan or doxorubicin also showed significantly enhanced anti-myeloma activity in vivo. These findings provide the basis for clinical development of these combination therapies.

References

Feb 17, 2000·Journal of Immunological Methods·Y T TaiK C Anderson
May 29, 2000·Journal of Cellular Physiology·W D Cress, E Seto
Dec 12, 2001·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·D N WaterhouseM B Bally
Jan 18, 2003·Blood·Nicholas MitsiadesKenneth C Anderson
Apr 16, 1965·Science·D E DE BERGSAGELK M GRIFFITH
Dec 30, 2003·Proceedings of the National Academy of Sciences of the United States of America·Constantine S MitsiadesKenneth C Anderson
Sep 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P Leif Bergsagel, W Michael Kuehl
Sep 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A Keith Stewart, Rafael Fonseca
Oct 26, 2005·Proceedings of the National Academy of Sciences of the United States of America·Yan ZhaoQiang Yu
Jan 19, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James R BerensonRegina Swift
Jan 24, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David Z QianRoberto Pili
Feb 24, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Chunrong YuAlex A Adjei
Mar 14, 2007·The Journal of Biological Chemistry·Hisako HigashitsujiJun Fujita
Aug 8, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert Z OrlowskiJean-Luc Harousseau
Aug 31, 2007·World Journal of Gastroenterology : WJG·Thilo BluethnerMarcus Wiedmann
Aug 30, 2008·The New England Journal of Medicine·Jesús F San MiguelUNKNOWN VISTA Trial Investigators
Dec 17, 2008·The New England Journal of Medicine·Anwarul Islam, Julian L Ambrus
Jun 11, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Giuseppe FlorisPatrick Schöffski

❮ Previous
Next ❯

Citations

Mar 26, 2013·Blood Cancer Journal·C Chang-Yew LeowA Spencer
Mar 13, 2012·Expert Opinion on Investigational Drugs·Paola NeriSagar Lonial
Feb 22, 2012·Upsala Journal of Medical Sciences·Helena Jernberg-Wiklund, Kenneth Nilsson
Jun 22, 2013·Clinical Lymphoma, Myeloma & Leukemia·Jonathan L KaufmanPaul G Richardson
Apr 22, 2016·International Journal of Hematology·Takeshi HaradaKenneth C Anderson
Dec 4, 2014·Therapeutic Advances in Hematology·Claudia V Andreu-Vieyra, James R Berenson
Mar 13, 2019·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Konstantinos Dimopoulos, Kirsten Grønbaek
May 10, 2017·Blood·Estefanía García-GuerreroMichael Hudecek
Jun 15, 2011·Expert Review of Hematology·Hang QuachAndrew Spencer
Jun 26, 2020·Frontiers in Cell and Developmental Biology·Linda Anna Michelle KulkaHeidi Olzscha
May 16, 2020·Journal of Oncology·Evangelos Eleutherakis-PapaiakovouMeletios Athanasios Dimopoulos
Mar 7, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Miguel LemaireKarin Vanderkerken
Mar 29, 2013·Molecular Cancer Therapeutics·Holly A F StessmanBrian G Van Ness
Aug 4, 2021·Clinical Lymphoma, Myeloma & Leukemia·Jesus G BerdejaAjai Chari

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Apoptotic Caspases

Apoptotic caspases belong to the protease enzyme family and are known to play an essential role in inflammation and programmed cell death. Here is the latest research.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.